// App-Quantinova.ai

: Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer.

Researchers

Presenter

  • David J. Vaughn

Principal Investigators

  • Ronald De Wit

  • Yves Fradet

  • Jae-Lyun Lee

  • Lawrence Fong

  • Nicholas J. Vogelzang

  • Miguel Angel Climent

  • Daniel Peter Petrylak

  • Toni K. Choueiri

  • Andrea Necchi

  • Winald R. Gerritsen

  • Howard Gurney

  • David I. Quinn

  • Stephane Culine

  • Cora N. Sternberg

  • Yabing Mai

  • Haojie Li

  • Rodolfo F. Perini

  • Dean F. Bajorin

Medical Centers

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Dana-Farber Cancer Institute, Boston, MA

  • Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

  • CHU de Quebec - Universite Laval, Quebec City, QC, Canada

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • University of California, San Francisco, San Francisco, CA

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain

  • Yale University School of Medicine, New Haven, CT

  • Dana-Farber/Harvard Cancer Center, Boston, MA

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Radboud University Medical Center, Njmegen, Netherlands

  • Westmead Hospital, Westmead, Australia

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Department of Medical Oncology, Hopital Saint-Louis, Paris, France

  • San Camillo-Forlanini Hospital, Rome, Italy

  • Merck & Co., Inc., Kenilworth, NJ

  • GlaxoSmithKline, Collegeville, PA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Netherlands

  • Canada

  • Spain

  • Italy

  • Australia

  • France

  • Republic of South Korea

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02256436

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved